Using an anti-CD25 immunotoxin (IT) for ex vivo selective depletion (SD), we recently showed that removal of host-reactive donor T cells is clinically feasible. Nevertheless, there was a concern that the removal of CD4ϩ CD25ϩ foxp3ϩ regulatory T cells (Tregs) by CD25-IT might favor GVHD. We therefore investigated photodepletion (PD), an alternative approach whereby alloactivated cells are labeled with the photosensitizing rhodaminebased dye TH9402, and exposure to light eliminates cells retaining the dye. PD may offer the possibility of conferring donor immunity without GVHD, permitting allo-SCT without the need for post-graft immunosuppression. Stimulator cells from human subjects were prepared from leukapheresis MNCs and cultured using anti-CD3 and 100 IU IL-2. Responder cells (leukapheresis MNCs) from HLA-mismatched volunteers were cocultured 1:1 with irradiated stimulators for 3 days. Cultured cells were incubated in TH9402 (5.0 and 7.5 microM), followed by exposure to 514 nm light in the PD light source (Celmed) at a cell concentration of 5 ϫ 10 6 /ml in FEP plastic bags (American Fluoroseal). Results were compared with the established small scale standard method. Depletion efficacy was studied by FACS and MLR. Effects on Tregs were investigated using foxp3 RT-PCR and intracellular foxp3 staining. In two large-scale experiments using cells from two donors, both the standard small-scale conditions and the large-scale conditions resulted in a 9 -18-fold and 21-42-fold reduction in alloreactivity when compared to the untreated MLR control on day ϩ1 and day ϩ4 after PD. Third-party responses were maintained. Effective depletion was observed despite the fact that a small fraction of CD25ϩ cells (2.7-3.3% of CD4ϩ cells) were still detectable by FACS on day ϩ4 after PD. RT-PCR for foxp3 in CD4-selected cells from the final SD product showed that a fraction of foxp3 mRNA was conserved. Intracellular foxp3 staining showed that foxp3ϩ Tregs persisted after PD, and represented 6% of CD4ϩ cells in untreated responder cells versus 2. Washing after thawing of frozen UCB used for hematopoietic stem cell transplantation (HSCT) is widely practiced for the purpose of removal of the cryoprotectant DMSO and free hemoglobin from lysed red cells; however, frozen peripheral blood stem cells with similar loads of free hemoglobin and DMSO are often thawed and infused directly without washing. Recently, similar clinical outcomes were seen with the standard red cell depleted (RCD) UCB, whether washing was employed after thawing or not. However, no data exist on the utility of post-thaw washing for UCB that were depleted of plasma (PD) but not depleted of red blood cells. A retrospective analysis was performed on the outcomes of 84 patients in remission without history of prior transplants, who received either washed (W; n ϭ 43) or non-washed (NW; n ϭ 40) PD UCB units for HSCT. Adverse events of any grade occurring more than once during infusion include hemoglobinuria (9 NW, 1 W), hypertension (6 NW, 4 W), hives (1 NW, 1 W), nausea/vomit (2 NW) and dyspnea (1 NW, 1 W). One patient developed seizure and encephalopathy following infusion of a NW PD UCB that resolved without any sequelae, although relationship to UCB infusion was uncertain. Total nucleated cell recovery after thawing as reported by transplant centers is higher for NW (median 95% vs 75%). Unadjusted cumulative incidence (U.C.I.) of neutrophil engraftment was similar for both groups, 91 Ϯ 5% for NW (n ϭ 36) versus 93 Ϯ 4% for W (n ϭ 41), but median time to neutrophil (20 vs 26 days) and platelet engraftment (platelet 20K 47 vs 55 days and platelet 50K 55 vs 63 days) occurred earlier for NW. U.C.I. for platelet 20K engraftment was higher for NW (n ϭ 28; 92 Ϯ 6%) than W (n ϭ 39; 75 Ϯ 7%). Acute grade III-IV GvHD were 10% (NW) and 19% (W), and extensive chronic GvHD were 0% (NW) and 22% (W). TRM were 18 Ϯ 6% (NW) and 20 Ϯ 7% (W), with relapse rate for malignant cases at 11 Ϯ 7% for NW and 25 Ϯ 8% for W. One-year OS was 75 Ϯ 7% (n ϭ 40) versus 72 Ϯ 8% (n ϭ 43), and 1-year DFS was 69 Ϯ 10% (n ϭ 23) versus 54 Ϯ 9% (n ϭ 34) for NW and W, respectively. No clear benefits of post-thaw washing for PD UCB prior to HSCT was found, except for the anticipated lower incidence of transient hemoglobinuria. HSCT with NW PD CBU was at least as efficacious as that using W PD units with respect to neutrophil engraftment, TRM, relapse rate, 1-year OS, and DFS. Moreover, washing may have a negative impact on U.C.I. of platelet engraftment and the speed of neutrophil and platelet engraftment.
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